CD44 reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 186, Issue 12, 2011, Pages 6955-6964

  Guan, Hongbing ^a   Nagarkatti, Prakash S ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 17; INTERLEUKIN 4; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OSTEOPONTIN; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DEMYELINATION; DISEASE CONTROL; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENETIC REGULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTIGENS, CD44; CELL DIFFERENTIATION; CYTOKINES; DNA METHYLATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPIGENESIS, GENETIC; MICE; PROMOTER REGIONS, GENETIC; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 79959536193     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004043     Document Type: Article

References (53)

1. Compston, A., and A. Coles. 2008. Multiple sclerosis. Lancet 372: 1502-1517.
2. Goverman, J. 2009. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9: 393-407.
3. Kasper, L. H., and J. Shoemaker. 2010. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74(Suppl. 1): S2-S8.
4. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A. Hafler. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
5. Hickey, W. F., B. L. Hsu, and H. Kimura. 1991. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28: 254-260.
6. Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057.
7. Aharoni, R., D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela, and R. Arnon. 2000. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA 97: 11472-11477.
8. Weber, M. S., T. Prod'homme, S. Youssef, S. E. Dunn, C. D. Rundle, L. Lee, J. C. Patarroyo, O. Stüve, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13: 935-943.
9. Steinman, L. 2007. A brief history of T(H)17, the first major revision in the T(H) 1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13: 139-145.
10. Qin, X., B. T. Guo, B. Wan, L. Fang, L. Lu, L. Wu, Y. Q. Zang, and J. Z. Zhang. 2010. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J. Immunol. 185: 1855-1863.
11. van Weering, D. H., P. D. Baas, and J. L. Bos. 1993. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl. 3: 100-106.
12. Naor, D., S. Nedvetzki, M. Walmsley, A. Yayon, E. A. Turley, I. Golan, D. Caspi, L. E. Sebban, Y. Zick, T. Garin, et al. 2007. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann. N. Y. Acad. Sci. 1110: 233-247.
13. Naor, D., S. Nedvetzki, I. Golan, L. Melnik, and Y. Faitelson. 2002. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 39: 527-579.
14. Seth, A., L. Gote, M. Nagarkatti, and P. S. Nagarkatti. 1991. T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc. Natl. Acad. Sci. USA 88: 7877-7881.
15. Chen, D., R. J. McKallip, A. Zeytun, Y. Do, C. Lombard, J. L. Robertson, T. W. Mak, P. S. Nagarkatti, and M. Nagarkatti. 2001. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J. Immunol. 166: 5889-5897. (Pubitemid 32440712)
16. McKallip, R. J., M. Fisher, Y. Do, A. K. Szakal, U. Gunthert, P. S. Nagarkatti, and M. Nagarkatti. 2003. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J. Biol. Chem. 278: 43818-43830.
17. Lesley, J., and R. Hyman. 1998. CD44 structure and function. Front. Biosci. 3: d616-d630.
18. Ponta, H., L. Sherman, and P. A. Herrlich. 2003. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4: 33-45.
19. Rafi-Janajreh, A. Q., P. S. Nagarkatti, and M. Nagarkatti. 1998. Role of CD44 in CTL and NK cell activity. Front. Biosci. 3: d665-d671.
20. Hegde, V. L., N. P. Singh, P. S. Nagarkatti, and M. Nagarkatti. 2008. CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J. Leukoc. Biol. 84: 134-142.
21. Guan, H., P. S. Nagarkatti, and M. Nagarkatti. 2009. Role of CD44 in the differentiation of Th1 and Th2 cells: CD44-deficiency enhances the development of Th2 effectors in response to sheep RBC and chicken ovalbumin. J. Immunol. 183: 172-180.
22. Bonder, C. S., S. R. Clark, M. U. Norman, P. Johnson, and P. Kubes. 2006. Use of CD44 by CD4+ Th1 and Th2 lymphocytes to roll and adhere. Blood 107: 4798-4806. (Pubitemid 43882631)
23. Mummert, M. E. 2005. Immunologic roles of hyaluronan. Immunol. Res. 31: 189-206.
24. Girgrah, N., M. Letarte, L. E. Becker, T. F. Cruz, E. Theriault, and M. A. Moscarello. 1991. Localization of the CD44 glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active lesions in multiple sclerosis. J. Neuropathol. Exp. Neurol. 50: 779-792.
25. Moretto, G., R. Y. Xu, and S. U. Kim. 1993. CD44 expression in human astrocytes and oligodendrocytes in culture. J. Neuropathol. Exp. Neurol. 52: 419-423.
26. Tuohy, T. M., N. Wallingford, Y. Liu, F. H. Chan, T. Rizvi, R. Xing, B. Bebo, M. S. Rao, and L. S. Sherman. 2004. CD44 overexpression by oligodendrocytes: a novel mouse model of inflammation-independent demyelination and dysmyelination. Glia 47: 335-345.
27. Back, S. A., T. M. Tuohy, H. Chen, N. Wallingford, A. Craig, J. Struve, N. L. Luo, F. Banine, Y. Liu, A. Chang, et al. 2005. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11: 966-972.
28. Chabas, D., S. E. Baranzini, D. Mitchell, C. C. Bernard, S. R. Rittling, D. T. Denhardt, R. A. Sobel, C. Lock, M. Karpuj, R. Pedotti, et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294: 1731-1735. (Pubitemid 33104847)
29. Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 168: 2096-2099. (Pubitemid 34171807)
30. Guan, H., P. S. Nagarkatti, and M. Nagarkatti. 2007. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J. Immunol. 179: 3715-3723.
31. Singh, N. P., V. L. Hegde, L. J. Hofseth, M. Nagarkatti, and P. Nagarkatti. 2007. Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 72: 1508-1521.
32. O'Connell, R. M., D. Kahn, W. S. Gibson, J. L. Round, R. L. Scholz, A. A. Chaudhuri, M. E. Kahn, D. S. Rao, and D. Baltimore. 2010. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33: 607-619.
33. Cottrell, S., K. Jung, G. Kristiansen, E. Eltze, A. Semjonow, M. Ittmann, A. Hartmann, T. Stamey, C. Haefliger, and G. Weiss. 2007. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J. Urol. 177: 1753-1758. (Pubitemid 46560648)
34. Partida-Sánchez, S., S. Goodrich, K. Kusser, N. Oppenheimer, T. D. Randall, and F. E. Lund. 2004. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 20: 279-291.
35. Thomas, R. M., C. Chen, N. Chunder, L. Ma, J. Taylor, E. J. Pearce, and A. D. Wells. 2010. Ikaros silences T-bet expression and interferon-gamma production during T helper 2 differentiation. J. Biol. Chem. 285: 2545-2553.
36. Lee, G. R., S. T. Kim, C. G. Spilianakis, P. E. Fields, and R. A. Flavell. 2006. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 24: 369-379.
37. Ansel, K. M., D. U. Lee, and A. Rao. 2003. An epigenetic view of helper T cell differentiation. Nat. Immunol. 4: 616-623.
38. Mullen, A. C., A. S. Hutchins, F. A. High, H. W. Lee, K. J. Sykes, L. A. Chodosh, and S. L. Reiner. 2002. Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat. Immunol. 3: 652-658.
39. Mummert, M. E., M. Mohamadzadeh, D. I. Mummert, N. Mizumoto, and A. Takashima. 2000. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J. Exp. Med. 192: 769-779.
40. Hur, E. M., S. Youssef, M. E. Haws, S. Y. Zhang, R. A. Sobel, and L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 8: 74-83.
41. Cantor, H., and M. L. Shinohara. 2009. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. 9: 137-141.
42. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
43. Cabbage, S. E., E. S. Huseby, B. D. Sather, T. Brabb, D. Liggitt, and J. Goverman. 2007. Regulatory T cells maintain long-term tolerance to myelin basic protein by inducing a novel, dynamic state of T cell tolerance. J. Immunol. 178: 887-896. (Pubitemid 46095161)
44. Hori, S., M. Haury, A. Coutinho, and J. Demengeot. 2002. Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in antimyelin basic protein T cell receptor transgenic mice. Proc. Natl. Acad. Sci. USA 99: 8213-8218.
45. Chen, M. L., B. S. Yan, D. Kozoriz, and H. L. Weiner. 2009. Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur. J. Immunol. 39: 3423-3435.
46. Nigam, P., V. Velu, S. Kannanganat, L. Chennareddi, S. Kwa, M. Siddiqui, and R. R. Amara. 2010. Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J. Immunol. 184: 1690-1701.
47. Karlsson, I., B. Malleret, P. Brochard, B. Delache, J. Calvo, R. Le Grand, and B. Vaslin. 2007. FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodeficiency virus infection in cynomolgus macaques correlates with low CD4+ T-cell activation and high viral load. J. Virol. 81: 13444-13455. (Pubitemid 350247840)
48. Laman, J. D., C. B. Maassen, M. M. Schellekens, L. Visser, M. Kap, E. de Jong, M. van Puijenbroek, M. J. van Stipdonk, M. van Meurs, C. Schwärzler, and U. Günthert. 1998. Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide. Mult. Scler. 4: 147-153.
49. Brocke, S., C. Piercy, L. Steinman, I. L. Weissman, and T. Veromaa. 1999. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA 96: 6896-6901.
50. Brennan, F. R., J. K. O'Neill, S. J. Allen, C. Butter, G. Nuki, and D. Baker. 1999. CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease. Immunology 98: 427-435. (Pubitemid 29526967)
51. Kennedy, M. K., D. S. Torrance, K. S. Picha, and K. M. Mohler. 1992. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149: 2496-2505.
52. Tuohy, V. K., M. Yu, L. Yin, P. M. Mathisen, J. M. Johnson, and J. A. Kawczak. 2000. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J. Neuroimmunol. 111: 55-63.
53. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537-546.